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Abstract 
 
This study uses monthly time series data on TB notifications at Zengeza clinic in Chitungwiza 
from January 2013 to December 2018; to forecast TB notifications using the Box & Jenkins 
(1970) approach to univariate time series analysis. Diagnostic tests indicate that TBN is an I (0) 
variable. Based on the AIC, the study presents the SARMA (2, 0, 2)(1, 0, 1)12 model, the 
diagnostic tests further show that this model is quite stable and hence acceptable for forecasting 
the TB notifications at Zengeza clinic. The selected optimal model shows that the TB 
notifications will decline over the out-of-sample period.  The main policy recommendation 
emanating from this study is that there should be continued intensification of TB surveillance 
and control programmes in order to reduce TB incidences not only at Zengeza clinic but also in 
Zimbabwe at large.  
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I. Introduction & Background 
Tuberculosis (TB), discovered by Robert Koch (1882), is an ancient scourge (Daniel, 2006); it 
has been known for centuries (Daniel & Daniel, 1999). In fact, the earliest detection of TB is 
associated with evidence of the disease in the remains of bison dated to nearly 17000 years ago. 
Scientists discovered tubercular decay in the spines of Egyptian mummies dating from 3000-
2400 BC (Crubezy, 2009). Mummies from the Egyptian pre-dynastic era and the Peruvian pre-
Columbian era show typical vertebral lesions (Cave, 1939; Morse et al, 1964). The first weak 
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evidence for TB in humans relies on lesions compatible with bone TB in a 500000 year-old skull 
in Turkey (Kappelman et al, 2008). The first undisputed evidence of “Mycobacterium 
Tuberculosis” was obtained by PCR sequencing and detection of mycobacteria lipids in bone 
lesions of a 17000 year-old bison found in Wyoming, USA (Rothchild et al, 2001; Lee et al, 
2012). The oldest evidence for human TB was found in Neolithic infant and woman in a 9000 
year-old settlement in the Eastern Mediterranean (Hershkovitz et al, 2008). 
TB is a respiratory infectious disease caused by “Mycobacterium Tuberculosis” (Ignatova et al, 
2006; Nasehi & Mirhaghghani, 2010; Ricks et al, 2011; Moosazadeh et al, 2013; Fogel, 2015; 
Dheda et al, 2016; Sharma et al, 2016) and spreads through air droplets by sneezing and 
coughing of the infected person (Ricks et al, 2011). TB can also result from reactivation of a past 
latent TB infection. Reactivation of TB is more common in countries that have controlled 
transmission properly, but recent transmission is more common in endemic countries (Dye et al, 
2002; Corbett et al, 2007; Nasehi et al, 2012). Persons with TB bacteria have a 5-15% lifetime 
risk of falling ill with TB; but people with compromised immune systems such as people living 
with HIV, malnutrition or diabetes, and those with tobacco use have much higher risk of falling 
ill (WHO, 2018). After, suffering from TB, if the patients are not given timely, thorough 
treatment, they can be faced with a serious threat to their health, even making them completely 
lose ability to work, but also possibly infecting others (Zheng et al, 2015). Although the global 
TB incidence has declined by 1-2% per year (Raviglione et al, 2012), it is still a major public 
health problem in many developing countries (Bele et al, 2014; Sgaragli & Frosini, 2016). 
Zengeza clinic is located in Chitungwiza, a high density dormitory town in Zimbabwe, which is 
affectionately known as “Chi Town”. The clinic is quite accessible by foot for those staying 
within the clinic’s vicinity and by public and private transport to those further afield. It is 
imperative to note that Zengeza clinic serves as the first medical point of entry for children and 
adults living in these suburbs. Zengeza clinic utilizes its proximity to the Chitungwiza Central 
Hospital, located only 3km away; and refers in-and out-patient cases for specialized care in 
emergency medicine, surgery as well as pediatrics. The clinic offers preventive, curative and 
diagnostic services which include immunizations (Zimbabwe expanded programme on 
immunization), voluntary medical male circumcision, maternity services, family planning 
services, treatment of chronic medical conditions, and treatment of infectious diseases such as 
TB, HTS (HIV Testing Services) as well as screening and testing for TB. 
The TB program at the city of Chitungwiza is funded by the government of Zimbabwe with the 
support of its partners, namely; The UNION, Challenge TB and USAID. Zengeza clinic has two 
main cadres who are responsible for coordinating and implementing the TB program, namely the 
TB focal person for the district and the TB focal nurse for the clinic. These focal persons report 
to the Sister-in-Charge for the clinic who then reports to the City Matron, who finally reports to 
the City Health Director. The clinic has nurses in each department who are capacitated to screen 
for TB and refer patients to Outpatient department where a presumptive diagnosis of TB is made 
and sputum samples are collected and sent to the clinic laboratory, where a confirmatory test is 
done. The clinic uses the Gene X-pert machine to detect MTB (Mycobacterium Tuberculosis). 
The machine is able to detect both drug sensitive TB and Rifampicin Resistant TB, thereby 
making it easy to start the patients on appropriate anti TB treatment promptly. 
Moreso, Directly Observed Treatment Support (DOTS) is also practised; this means that health 
workers and treatment supporters directly observe patients as they take their daily medications. 
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Treatment follow up is done by clinic nurses with the help of the focal person and TB 
coordinator. Treatment cure is done by doing sputum microscopy, culture and sensitivity testing 
at the end of the treatment course, for example, 6 months for Drug Sensitive TB. A sputum 
negative sample means no MTB is detected and thus the patient is cured. A sputum positive 
sample means that the patient is still suffering from TB and drug resistance has developed, 
therefore a different class of anti-TB drugs is required since the resistance to rifampicin and 
isoniazid has developed. Hence, in this regard, injectable anti TB drugs are required. 
The district uses a mobile X-ray machine to detect sputum negative pulmonary TB and the 
radiological features are cavitary lesions, lung consolidation and pleural effusion. Complicated 
presumptive TB cases are reffered to Chitungwiza Central Hospital where further tests are done 
which include ultrasonography, CT scanning and biochemistry tests. Additionally, there is an 
observable HIV/TB collaboration where all HIV positive clients are screened for TB and all TB 
patients are tested for HIV and commenced on treatment promptly when they test positive. The 
clinic’s Health Education and Promotion department is seized with awareness programs in the 
community in order to help reduce the burden of TB. This research focuses on Zengeza clinic TB 
notifications and seeks to achieve the following objectives:  
Objectives of the Study 
i. To analyze the trend of TB notifications under the study period.  
ii. To determine the forecasted number of TB notifications over the period January 2019 to 
December 2030.  
Statement of the Problem 
Despite the discovery of the causative agent more than a century ago, a vaccine, highly effective 
medications, and recent improvement in biological molecular field and genetic engineering, TB 
remains a major public health concern in the world (Dye, 2006; Zheng et al, 2015; Ade et al, 
2016) with a vast health burden due to the high incidence, medical expenses, drug resistance and 
co-infections (WHO, 2016; Marais & Sintchenko, 2017). TB is one of the biggest health 
challenges which the world is facing and is the second major cause of mortality, especially in 
poor and low economic countries (WHO, 2001; Glaziou et al, 2009; Liu et al, 2010; Lin & Liao, 
2013; Glaziou et al, 2014). 95% of TB cases and 98% of TB deaths occur in low and middle 
income families (WHO, 2000). Globally, in 2014 alone, there was an estimated 9.6 million 
incident cases, of which 1.5 million were estimated to have died. The burden of TB is particulary 
immense in Africa from where the case rate is approximately 281 per 100000 people (WHO, 
2015). TB is a significant public health problem in Zimbabwe (Dube, 2015) and continues to be 
a significant cause of morbidity and mortality in Zimbabwe (National TB Guidelines, 2010). 
Zimbabwe is among the 22 countries in the world, reffered to as “the TB high burden countries” 
and has an estimated TB incidence per capita of 603 per 100000 population (WHO, 2014). In 
Zimbabwe, besides full implementation of national TB programs, TB still continues to be a 
leading cause of mortality and economic burden. The major causes for vulnerable situation of TB 
in Zimbabwe include but are not limited to poverty, malnutrition, high prevalence of HIV/AIDS 
and lack of awareness and education. In Chitungwiza district, just like in any other district in 
Zimbabwe, TB is a major health problem. The results of this paper are envisioned to go a long 
way in assisting health policy makers in reducing the TB burden not only at Zengeza clinic but 
also in Zimbabwe at large.   
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Significance of the Study 
This paper is, in line with the “End TB Strategy” of the WHO launched in 2014 whose targets 
are that of reducing by 2035 the incidence and mortality of TB by 90% and 95% respectively. 
The paper is also consistent with the Zimbabwe National TB Control Strategy’s vision of “A TB-
free Zimbabwe”. It is almost unnecessary to reiterate the fact that in order to attain the 2020 
milestones of the “End TB Strategy” and the Zimbabwe National TB Control Strategy, there is 
need for additional and relevant TB modeling and forecasting techniques at all levels. From a 
micro-level analysis, this study is envisioned to enhance the understanding of the past and 
current epidemiology of TB in Zimbabwe. 
II. Literature Review 
Table 1: Previous Studies Reviewed 
Author(s)/Year Country Period  Methodology  Key Findings 
Imran et al (2014) Pakistan 2001 – 2011  ARIMA ARIMA (3, 1, 0) model 
was the best model. 
Moosazadeh et al (2014) Iran January 2005 – 
December 2011 
SARIMA  SARIMA (0, 1, 1)(0, 1, 
1)12 model was the 
optimal model. 
Dube (2015) Zimbabwe 1990 – 2013  ARIMA, ARCH, HW Best models were found 
to be the ARIMA (2, 2, 1) 
and ARIMA (2, 2, 1)-
ARCH (1) models.  
Azeez et al (2016) South Africa January 2010 – 
December 2015  
SARIMA, SARIMA-
NNAR 
The SARIMA-NNAR 
model was the best 
model. 
Patowary & Barman (2017) India 2001 – 2011  SARIMA The optimal model was 
the SARIMA (0, 0, 0)(1, 
1, 0)4.  
Anggraeni et al (2017) Indonesia January 2007 – 
September 2016 
ARIMAX The best model is the 
ARIMAX (3, 1, 0).  
Mao et al (2018) China January 2004 – 
December 2015 
SARIMA The best fit model was the 
SARIMA (1, 0, 0)(0, 1, 
1)12. 
Mohammed et al (2018) Iraq January 2010 – 
December 2016 
SARIMA, SARIMA-
NNAR, SARIMA-ETS, 
SARIMA-ANFIS 
The optimal model was 
the SARIMA-ANFIS 
model.  
Aryee et al (2018) Ghana January 2008 – 
December 2017 
ARIMA ARIMA (1, 0, 1) or 
ARMA (1, 1) model was 
the best model.  
Liu et al (2019) China January 2005 – 
December 2015  
SARIMA, BPNN BPNN model performs 
better than the SARIMA 
model.  
As shown in table 1 above, 60% of the reviewed previous studies, that is; Moosazadeh et al 
(2014), Azeez et al (2016), Patowary & Barman (2017), Mao et al (2018), Mohammed et al 
(2018) and Liu et al (2019); have used the SARIMA technique in modeling and forecasting TB, 
and this clearly confirms the increasing popularity of SARIMA models in analyzing TB trends. 
Half of these studies (Moosazadeh et al, 2014; Patowary & Barman, 2017; Mao et al, 2018) have 
concluded that the SARIMA model is suitable for modeling and forecasting TB. Only 40% of the 
reviewed previous studies have used other analysis techniques such as generalized ARIMA, 
ARCH and HW (Imran et al, 2014; Dube, 2015; Aryee et al, 2018) and ARIMAX (Anggraeni et 
al, 2017). Other researchers have also attempted using hybrid models such as BPNN (Liu et al, 
2019) and SARIMA-NNAR, SARIMA-ETS as well as SARIMA-ANFIS (Azeez et al, 2016; 
Mohammed et al, 2018). However, Azeez et al (2016) concluded that their hybrid model, the 
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SARIMA-NNAR model performed better than generalized SARIMA models. Similarly, Liu et al 
(2019); finally noted that their hybrid model, the BPNN model was superior to SARIMA models. 
In line with previous studies such as Moosazadeh et al (2014), Patowary & Barman (2017) and 
Mao et al (2018); this research employs the SARIMA technique to model and forecast TB 
notifications at Zengeza clinic in Chitungwiza.   
III. Methodology 
The SARIMA Model 
A general SARIMA model may, thus, be specified as shown in equation [1] below: ɸ𝑝(𝐵)∅𝑝(𝐵𝑠)𝑇𝐵𝑁𝑡 = 𝜃𝑞(𝐵)𝛩𝑞(𝐵𝑠)𝜀𝑡 … … … … … … … . … … … … … . . … … … … . [1] 
Where B is the backshift operator, ɸ𝑝, ∅𝑝, 𝜃𝑞 𝑎𝑛𝑑 𝛩𝑞 are polynomials of order p, P, q and Q 
respectively. 𝜀𝑡 is a white noise process and 𝑇𝐵𝑁𝑡 = ∇𝑑∆𝑠𝐷𝑌𝑡 is the differenced TBN series. If 
the series are stationary in levels, equation [1] becomes a SARMA [Seasonal ARMA] model.   
The Box – Jenkins Technique 
The first step towards model selection is to difference the series in order to achieve stationarity. 
Once this process is over, the researcher will then examine the correlogram in order to decide on 
the appropriate orders of the AR and MA components. It is important to highlight the fact that 
this procedure (of choosing the AR and MA components) is biased towards the use of personal 
judgement because there are no clear – cut rules on how to decide on the appropriate AR and 
MA components. Therefore, experience plays a pivotal role in this regard. The next step is the 
estimation of the tentative model, after which diagnostic testing shall follow. Diagnostic 
checking is usually done by generating the set of residuals and testing whether they satisfy the 
characteristics of a white noise process. If not, there would be need for model re – specification 
and repetition of the same process; this time from the second stage. The process may go on and 
on until an appropriate model is identified (Nyoni, 2018). The Box – Jenkins technique is 
accredited to Box & Jenkins (1970) and in this research; it will be used for analyzing monthly 
TB Notifications for Zengeza clinic in Chitungwiza, Harare, Zimbabwe.  
Data  
This study is based on monthly observations of TB notifications (TBN) at Zengeza clinic, 
Chitungwiza, Zimbabwe, from January 2013 to December 2018. Our out-of-sample forecast 
ranges over the period January 2019 to December 2030. All the data employed in this research 
was gathered from Zengeza clinic. 
Diagnostic Tests and Model Evaluation for TB notifications 
Stationarity Tests: Graphical Analysis  
Figure 1: Graphical Analysis 
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The Correlogram in Levels 
Figure 2: Correlogram in Levels 
 
The ADF Test 
Table 2: Levels-intercept 
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Variable ADF Statistic Probability Critical Values Conclusion 
TBN -5.128440 0.0001 -3.525618 @1% Stationary  
  -2.902953 @5% Stationary 
  -2.588902 @10% Stationary 
Table 3: Levels-trend & intercept 
Variable ADF Statistic Probability Critical Values Conclusion 
TBN -5.092354 0.0004 -4.092547 @1% Stationary  
  -3.474363 @5% Stationary 
  -3.164499 @10% Stationary 
Table 4: without intercept and trend & intercept 
Variable ADF Statistic Probability Critical Values Conclusion 
TBN -2.301511 0.0216 -2.597939 @1% Not stationary  
  -1.945456 @5% Stationary 
  -1.613799 @10% Stationary 
Figures 1 and 2 as well as tables 2 – 4 show that the series under consideration is I(0).  
Evaluation of SARMA Models (without a constant) 
Table 5: Evaluation of SARMA Models (with a constant) 
Model AIC  ME RMSE MAE 
SARMA (1, 0, 1)(0, 0, 0)12 398.5972 -0.035141 3.6501 2.9732 
SARMA (1, 0, 1)(0, 0, 1)12 400.5226 -0.027931 3.648 2.9605 
SARMA (1, 0, 1)(1, 0, 1)12 401.9278 -0.017039 3.6314 2.9512 
SARMA (1, 0, 1)(1, 0, 0)12 400.5007 -0.025775 3.6474 2.9574 
SARMA (2, 0, 2)(0, 0, 0)12 393.8185 0.026317 3.4311 2.8932 
SARMA (2, 0, 2)(0, 0, 1)12 395.1647 -0.00011013 3.4154 2.8775 
SARMA (2, 0, 2)(1, 0, 1)12 389.1094 0.056132 3.2588 2.7139 
SARMA (2, 0, 2)(1, 0, 0)12 395.002 -0.0056874 3.4115 2.8754 
SARMA (0, 0, 0)(1, 0, 1)12 414.2855 0.045798 4.0632 3.1871 
SARMA (0, 0, 1)(1, 0, 1)12 403.8767 0.015386 3.7292 2.9694 
SARMA (1, 0, 0)(1, 0, 1)12 399.9407 -0.014318 3.6316 2.9446 
The study uses the AIC as the goodness of fit criterion. A model with the lowest AIC value is the 
optimal model. Thus, the SARMA (2, 0, 2)(1, 0, 1)12 model is selected as the optimal model. It is 
imperative to note that the selected optimal model also satisfies the law of parsimony or the rule 
of thumb represented by the following equality:  𝑝 + 𝑑 + 𝑞 + 𝑃 + 𝐷 + 𝑄 ≤ 6 … … … … … … … … … … … … … … … … … … … … . . … … … … … … … . [2] 
Residual Test of the Selected Model 
Residual Correlogram of the selected SARIMA (2, 0, 2)(1, 0, 1)12 Model  
Figure 3: Residual Correlogram of the SARMA (2, 0, 2)(1, 0, 1)12 Model 
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Figure 6 shows that the residuals of the SARIMA (2, 0, 2)(1, 0, 1)12 model are stable and 
stationary.  
IV. Findings of the Study 
Descriptive Statistics 
Table 6: Descriptive Statistics 
Description Statistic (TBN) 
Mean 7.8889 
Median 7 
Minimum 0 
Maximum 23 
Standard deviation 4.1267 
Skewness 0.89712 
Excess kurtosis 1.3113 
As shown in table 6 above, the mean is positive, that is, 7.8889. The median is 7. The minimum 
is 0 while the maximum is 23. The skewness is 0.89712 and is positive, implying that the 
variable TBN is positively skewed and non-symmetric. Excess kurtosis is 1.3113 and this shows 
that TBN is normally distributed.  
Results Presentation1  
Table 7: Results Presentation – the SARMA (2, 0, 2)(1, 0, 1)12 
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Variable  Coefficient Std. Error z p-value 
const 7.90221 0.908032 8.703 0.0001*** 
phi_1 1.42490 0.0870945 16.36 0.0001*** 
phi_2 −0.929864 0.0841586 −11.05 0.0001*** 
Phi_1 1.34338 0.372536 3.606 0.0003*** 
theta_1 −1.17446 0.139200 −8.437 0.0001*** 
theta_2 0.842463 0.124570 6.763 0.0001*** 
Theta_1 −0.910665 0.991293 −0.9187 0.3583 
     
 
Equation 1 can be used to mathematically present the results in table 7 as shown below: 
 ɸ1(𝐵)∅2(𝐵12)𝑇𝐵𝑁𝑡 = 𝜃1(𝐵)𝛩2(𝐵12)𝜀𝑡 … … … … … … . … … … … … . . … … … … . [3] 
 
Figure 4: Graph showing both in-sample and out-of-sample forecasts 
 
Table 8: Predicted TB Notifications for Zengeza Clinic (2019 – 2030) 
 Year: Month Prediction Standard Error 95% Confidence Interval 
2019:01 10.4997 3.91998 (2.81666, 18.1827) 
2019:02 13.3397 4.04104 (5.41940, 21.2600) 
2019:03 10.2638 4.17680 (2.07737, 18.4501) 
2019:04 11.4514 4.21857 (3.18317, 19.7197) 
2019:05 6.25743 4.22084 (-2.01527, 14.5301) 
2019:06 6.26821 4.28657 (-2.13332, 14.6697) 
2019:07 0.0656059 4.38776 (-8.53425, 8.66547) 
2019:08 0.952782 4.43414 (-7.73797, 9.64353) 
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2019:09 5.94480 4.43432 (-2.74631, 14.6359) 
2019:10 10.9821 4.46677 (2.22740, 19.7368) 
2019:11 8.75315 4.53841 (-0.141976, 17.6483) 
2019:12 7.86276 4.58398 (-1.12168, 16.8472) 
2020:01 10.2565 4.95000 (0.554648, 19.9583) 
2020:02 9.95614 4.95049 (0.253353, 19.6589) 
2020:03 4.64849 4.95487 (-5.06287, 14.3598) 
2020:04 8.39586 4.96805 (-1.34135, 18.1331) 
2020:05 5.57768 4.97847 (-4.17995, 15.3353) 
2020:06 9.51780 4.97998 (-0.242780, 19.2784) 
2020:07 2.91145 4.98155 (-6.85220, 12.6751) 
2020:08 2.91244 4.99009 (-6.86796, 12.6928) 
2020:09 6.31678 4.99908 (-3.48125, 16.1148) 
2020:10 9.48631 5.00150 (-0.316455, 19.2891) 
2020:11 4.43617 5.00183 (-5.36723, 14.2396) 
2020:12 3.65586 5.00693 (-6.15753, 13.4693) 
2021:01 9.37564 5.39524 (-1.19884, 19.9501) 
2021:02 12.1537 5.40987 (1.55053, 22.7568) 
2021:03 7.22832 5.44499 (-3.44365, 17.9003) 
2021:04 12.4457 5.46882 (1.72707, 23.1644) 
2021:05 6.87088 5.47094 (-3.85198, 17.5937) 
2021:06 9.44434 5.47697 (-1.29032, 20.1790) 
2021:07 -1.64208 5.50045 (-12.4228, 9.13861) 
2021:08 -2.26326 5.52178 (-13.0857, 8.55922) 
2021:09 3.47953 5.52610 (-7.35143, 14.3105) 
2021:10 9.98268 5.52786 (-0.851722, 20.8171) 
2021:11 5.31026 5.54244 (-5.55272, 16.1732) 
2021:12 5.18335 5.56011 (-5.71425, 16.0810) 
2022:01 12.2163 6.47519 (-0.474856, 24.9074) 
2022:02 14.1641 6.51529 (1.39434, 26.9338) 
2022:03 5.61044 6.53612 (-7.20012, 18.4210) 
2022:04 11.5183 6.53652 (-1.29298, 24.3297) 
2022:05 4.26148 6.54770 (-8.57177, 17.0947) 
2022:06 9.07341 6.57622 (-3.81574, 21.9626) 
2022:07 -4.10534 6.59644 (-17.0341, 8.82344) 
2022:08 -3.75663 6.59854 (-16.6895, 9.17626) 
2022:09 4.04979 6.60300 (-8.89185, 16.9914) 
2022:10 11.8164 6.62195 (-1.16237, 24.7952) 
2022:11 4.07282 6.63988 (-8.94110, 17.0867) 
2022:12 2.71388 6.64384 (-10.3078, 15.7356) 
2023:01 11.8322 7.74760 (-3.35281, 27.0172) 
2023:02 15.0844 7.77367 (-0.151757, 30.3205) 
2023:03 4.80562 7.80204 (-10.4861, 20.0973) 
2023:04 13.8782 7.81015 (-1.42942, 29.1858) 
2023:05 4.62123 7.81094 (-10.6879, 19.9304) 
2023:06 10.7298 7.82626 (-4.60940, 26.0690) 
2023:07 -7.93829 7.84875 (-23.3216, 7.44498) 
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2023:08 -8.51280 7.85849 (-23.9151, 6.88956) 
2023:09 1.38448 7.85849 (-14.0179, 16.7868) 
2023:10 11.9475 7.86657 (-3.47064, 27.3657) 
2023:11 2.27797 7.88325 (-13.1729, 17.7288) 
2023:12 1.37630 7.89334 (-14.0944, 16.8470) 
2024:01 14.2605 9.68736 (-4.72634, 33.2474) 
2024:02 18.6750 9.75461 (-0.443682, 37.7937) 
2024:03 4.34138 9.81214 (-14.8901, 23.5728) 
2024:04 15.7382 9.82239 (-3.51335, 34.9897) 
2024:05 2.66399 9.82853 (-16.5996, 21.9276) 
2024:06 10.6957 9.87076 (-8.65068, 30.0420) 
2024:07 -14.0372 9.91896 (-33.4780, 5.40359) 
2024:08 -14.1548 9.93384 (-33.6247, 5.31520) 
2024:09 -0.247898 9.93474 (-19.7196, 19.2238) 
2024:10 14.2047 9.95908 (-5.31476, 33.7241) 
2024:11 1.02048 9.99677 (-18.5728, 20.6138) 
2024:12 -0.711704 10.0141 (-20.3390, 18.9156) 
2025:01 16.0351 12.4834 (-8.43196, 40.5022) 
2025:02 21.6496 12.5570 (-2.96166, 46.2609) 
2025:03 2.46640 12.6196 (-22.2675, 27.2003) 
2025:04 18.1731 12.6306 (-6.58236, 42.9285) 
2025:05 1.10741 12.6374 (-23.6615, 25.8764) 
2025:06 12.2376 12.6838 (-12.6222, 37.0975) 
2025:07 -20.9654 12.7364 (-45.9283, 3.99760) 
2025:08 -21.4080 12.7525 (-46.4025, 3.58649) 
2025:09 -3.15249 12.7536 (-28.1490, 21.8440) 
2025:10 15.9196 12.7804 (-9.12955, 40.9687) 
2025:11 -1.88400 12.8217 (-27.0140, 23.2460) 
2025:12 -4.02334 12.8405 (-29.1902, 21.1435) 
2026:01 18.8271 16.2773 (-13.0758, 50.7299) 
2026:02 26.6982 16.3877 (-5.42119, 58.8175) 
2026:03 1.06794 16.4867 (-31.2453, 33.3812) 
2026:04 22.0618 16.5062 (-10.2898, 54.4134) 
2026:05 -1.14529 16.5148 (-33.5137, 31.2231) 
2026:06 13.5044 16.5833 (-18.9981, 46.0070) 
2026:07 -31.2688 16.6651 (-63.9318, 1.39434) 
2026:08 -31.8232 16.6923 (-64.5395, 0.893110) 
2026:09 -7.08468 16.6932 (-39.8028, 25.6335) 
2026:10 18.8045 16.7321 (-13.9897, 51.5988) 
2026:11 -4.92953 16.7954 (-37.8479, 27.9889) 
2026:12 -7.79246 16.8262 (-40.7712, 25.1862) 
2027:01 22.7499 21.5641 (-19.5150, 65.0149) 
2027:02 33.0937 21.7135 (-9.46404, 75.6514) 
2027:03 -1.52171 21.8419 (-44.3311, 41.2876) 
2027:04 26.6321 21.8650 (-16.2226, 69.4868) 
2027:05 -4.44175 21.8785 (-47.3227, 38.4392) 
2027:06 15.4290 21.9721 (-27.6357, 58.4936) 
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2027:07 -44.5414 22.0796 (-87.8166, -1.26626) 
2027:08 -45.2115 22.1130 (-88.5522, -1.87087) 
2027:09 -12.0364 22.1149 (-55.3808, 31.3080) 
2027:10 22.5905 22.1688 (-20.8596, 66.0405) 
2027:11 -9.45608 22.2527 (-53.0706, 34.1585) 
2027:12 -13.3926 22.2915 (-57.0832, 30.2979) 
2028:01 27.6596 28.6947 (-28.5809, 83.9001) 
2028:02 41.6712 28.8947 (-14.9613, 98.3037) 
2028:03 -4.68569 29.0704 (-61.6626, 52.2912) 
2028:04 33.2335 29.1037 (-23.8087, 90.2757) 
2028:05 -8.50498 29.1203 (-65.5798, 48.5698) 
2028:06 18.1052 29.2450 (-39.2138, 75.4243) 
2028:07 -62.5816 29.3911 (-120.187, -4.97599) 
2028:08 -63.5808 29.4382 (-121.279, -5.88304) 
2028:09 -19.0400 29.4403 (-76.7419, 38.6619) 
2028:10 27.5323 29.5114 (-30.3091, 85.3736) 
2028:11 -15.4154 29.6250 (-73.4793, 42.6485) 
2028:12 -20.6085 29.6789 (-78.7780, 37.5611) 
2029:01 34.5799 38.3622 (-40.6087, 109.769) 
2029:02 53.3710 38.6355 (-22.3531, 129.095) 
2029:03 -8.98581 38.8735 (-85.1765, 67.2049) 
2029:04 41.8663 38.9178 (-34.4112, 118.144) 
2029:05 -14.2527 38.9412 (-90.5760, 62.0707) 
2029:06 21.5073 39.1119 (-55.1506, 98.1651) 
2029:07 -86.8226 39.3102 (-163.869, -9.77593) 
2029:08 -88.0871 39.3733 (-165.257, -10.9169) 
2029:09 -28.1994 39.3764 (-105.376, 48.9768) 
2029:10 34.3671 39.4741 (-43.0006, 111.735) 
2029:11 -23.3730 39.6285 (-101.043, 54.2975) 
2029:12 -30.4162 39.7010 (-108.229, 47.3964) 
2030:01 43.6693 51.3936 (-57.0603, 144.399) 
2030:02 68.8992 51.7591 (-32.5468, 170.345) 
2030:03 -14.8393 52.0781 (-116.911, 87.2320) 
2030:04 53.5296 52.1377 (-48.6583, 155.718) 
2030:05 -21.8080 52.1688 (-124.057, 80.4410) 
2030:06 26.2523 52.3970 (-76.4439, 128.948) 
2030:07 -119.293 52.6627 (-222.510, -16.0756) 
2030:08 -121.036 52.7474 (-224.419, -17.6527) 
2030:09 -40.6313 52.7515 (-144.022, 62.7597) 
2030:10 43.3931 52.8820 (-60.2538, 147.040) 
2030:11 -34.1666 53.0888 (-138.219, 69.8855) 
2030:12 -43.5943 53.1861 (-147.837, 60.6485) 
 
Figure 5: Graph showing out-of-sample forecasts only 
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Table 6 shows the main results of the SARMA (2, 0, 2)(1, 0, 1)12 model for Zengeza clinic TB 
notifications. Equation [3] is a mathematical representation of the model tabulated in table 6. 
Figure 4 and 5 as well as table 7 show the predicted TB notifications over the period 2019 – 
2030. It is imperative to note that TB notifications are generally likely to fall over the out-of-
sample forecast as shown in figures 4 and 5 and table 7. Our results are consistent with WHO 
(2018i) which highlighted that the disease burden caused by TB is falling globally, in all WHO 
regions, and in most countries, but not fast enough to reach the first (2020) milestones of the End 
TB Strategy. The following reasons account for the anticipated fall in TB notifications at 
Zengeza clinic: 
i. Early case detection and early treatment of all TB cases, thereby reducing the spread of 
TB infection in the community.  
ii. Follow up of treatment defaulters and ensuring that they take their treatment thereby 
reducing the risk of developing drug resistance which may make it difficult to treat and 
control the spread of the disease. 
iii. TB awareness in the community and increased community participation in identification 
and treatment of sputum positive TB patients. 
iv. Isoniazid (INH) prophylaxis for children under 5 years who are in contact with sputum 
positive TB patients and also INH prophylaxis for all HIV positive patients who have no 
contraindications and have been screened for TB. 
v. HIV/TB collaboration in the clinic. 
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V. Recommendations & Conclusion 
TB remains a threat to public health in Zimbabwe and continuous monitoring of this epidemic is 
not unimportant for its control and intervention, in order to reduce morbidity and mortality 
caused by this disease. The study recommends the intensification of TB surveillance and control 
programmes in order to reduce TB incidences not only at Zengeza clinic but also in Zimbabwe at 
large. The current study relied on 72 monthly observations of TB notifications at Zengeza clinic 
(January 2013 – December 2018) to model and forecast 144 out-of-sample TBNs, that is, from 
January 2019 to December 2030. We employed the Box-Jenkins SARMA approach. The study 
showed that TB notifications are expected to decline over the out-of-sample period. It is 
important to note that the data employed is generally limited: further research should make use 
of a wide data set on the basis that univariate time series models perform better when applied 
over longer time series data. While it is a fact that Box-Jenkins models are increasingly 
becoming popular in modeling and forecasting communicable diseases such as TB, it would be 
good as well for researchers to explore other forecasting techniques such as the use of Artificial 
Neural Networks (ANNs) and ARIMAX models.  
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